Cure My Disease

Don't miss your cure!

 Log in / Sign up

New Armpit-Incision mastectomy could leave breasts Scar-Free

NCT ID NCT06569706

Symptom relief Sponsor: University Hospital, Montpellier Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new way to remove breast cancer through a single small cut in the armpit, leaving no visible scar on the breast. It is for women with small to medium breasts who need a mastectomy but want to keep their nipple. The procedure uses standard laparoscopic tools, making it cheaper than robotic surgery. The goal is to see if it is safe and works well in a French hospital.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Endoscopic nipple-sparing mastectomy with immediate breast reconstruction (a surgical procedure using a single port through the armpit)
What this could lead to
If successful, this could offer breast cancer patients a less visible scar option for mastectomy, potentially improving cosmetic outcomes and recovery.
What could go wrong
This is a very small early feasibility study with only 20 participants, so results may not apply to everyone. The procedure is new to Europe and may have higher complication rates or need conversion to open surgery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2024

Expected to finish

Oct 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 to 75 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Women between 20 and 75 years. * Patient with an indication for curative mastectomy, either unilateral or bilateral, with nipple preservation: * Extensive Carcinoma In Situ (CIS), more than 2 cm from the nipple * Multicentric Infiltrating Carcinoma (IC), more than 2 cm from the nipple * Large volume Infiltrating Carcinoma, more than 2 cm from the nipple * IC or CIS for which the patient refuses conservative treatment, more than 2 cm from the nipple * Breast volumes: cup sizes A, B, or C as defined by underwear size, and glandular ptosis not exceeding grade 2 according to Regnault's classification * Patient wishing to undergo immediate breast reconstruction. * WHO/OMS (World Health Organization/Organisation Mondiale de la Santé) performance status \<3 Exclusion Criteria: * Cutaneous carcinoma * Inflammatory breast * History of oncological breast surgery on the same breast * Patient who has received radiation treatment on the same breast * Breast hypertrophy requiring a nipple-bearing flap * Smoking ≥ 10 cigarettes/day * BMI \> 35 * Protected patient or unable to give consent according to Article L1121-8 of the French Public Health Code (CSP). * Patient participating in another interventional clinical study. * ASA (physical status score of the American Society of Anesthesiologists) \>2. * Pregnant or breastfeeding women according to Article L1121-5 of the CSP. * Vulnerable persons (those receiving psychiatric care, those deprived of liberty, and those admitted to a health or social institution) according to Article L1121-6 of the CSP. * Absence of effective contraception for patients of childbearing age. * Absence of affiliation with a social security scheme. * Absence of collected free, informed, and written consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Uhmontpellier

    RECRUITING

    Montpellier, 34295, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.